» Articles » PMID: 17934452

Simultaneous Targeting of Multiple Disease Mediators by a Dual-variable-domain Immunoglobulin

Abstract

For complex diseases in which multiple mediators contribute to overall disease pathogenesis by distinct or redundant mechanisms, simultaneous blockade of multiple targets may yield better therapeutic efficacy than inhibition of a single target. However, developing two separate monoclonal antibodies for clinical use as combination therapy is impractical, owing to regulatory hurdles and cost. Multi-specific, antibody-based molecules have been investigated; however, their therapeutic use has been hampered by poor pharmacokinetics, stability and manufacturing feasibility. Here, we describe a generally applicable model of a dual-specific, tetravalent immunoglobulin G (IgG)-like molecule--termed dual-variable-domain immunoglobulin (DVD-Ig)--that can be engineered from any two monoclonal antibodies while preserving activities of the parental antibodies. This molecule can be efficiently produced from mammalian cells and exhibits good physicochemical and pharmacokinetic properties. Preclinical studies of a DVD-Ig protein in an animal disease model demonstrate its potential for therapeutic application in human diseases.

Citing Articles

Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence.

Hushmandi K, Einollahi B, Lee E, Sakaizawa R, Glaviano A, Reiter R Int J Biol Sci. 2025; 21(4):1410-1435.

PMID: 39990653 PMC: 11844292. DOI: 10.7150/ijbs.96155.


Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows.

Fawcett C, Tickle J, Coles C MAbs. 2024; 16(1):2311992.

PMID: 39674918 PMC: 10883111. DOI: 10.1080/19420862.2024.2311992.


Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors.

Gu Y, Zhao Q Mol Diagn Ther. 2024; 28(6):669-702.

PMID: 39172329 PMC: 11512917. DOI: 10.1007/s40291-024-00734-w.


Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies.

Mohan N, Ayinde S, Peng H, Dutta S, Shen Y, Falkowski V Front Immunol. 2024; 15:1376096.

PMID: 38863707 PMC: 11165055. DOI: 10.3389/fimmu.2024.1376096.


Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern.

Rubio A, Baharani V, Dadonaite B, Parada M, Abernathy M, Wang Z bioRxiv. 2024; .

PMID: 38766244 PMC: 11100608. DOI: 10.1101/2024.05.05.592584.